Peptide Registry

Vials

Capsules

Liquids

a vial of Adipotide 10mg
an info card for Adipotide

Adipotide

Price range: $42.00 through $76.00

  • Contents: Adipotide (FTPP; CKGGRAKDC-(GG)-(KLAKLAK)₂)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - -
4 - 7 10% -
8 + 18% -
SKU: N/A Categories: , Brand:

Description

Adipotide is a synthetic bifunctional peptidomimetic that the University of Texas MD Anderson Cancer Center Renata Pasqualini and Wadih Arap developed. It applies the vascular-targeted proapoptotic peptide (VTAPP) architecture, originally developed for tumor vasculature targeting, to the vasculature of white adipose tissue. The compound consists of two functional domains joined by a glycine-glycine linker. Adipotide is a research tool in both adipose tissue biology and specialty research peptide oncology vascular models. However, unlike AOD-9604, Adipotide directly targets and eliminates the endothelial cells supplying the tissue rather than modulating metabolic signaling within it.

Chemical Information

  • Chemical Name: Fat-Targeted Proapoptotic Peptide (FTPP); Prohibitin-Targeting Peptide-1 (TP01)
  • Also Known As: FTPP; TP01; Prohibitin-Targeting Peptide-1
  • Homing Domain: CKGGRAKDC (cyclic; prohibitin/annexin A2 targeting)
  • Proapoptotic Domain: (KLAKLAK)2 (amphipathic; mitochondrial membrane disruption)
  • Linker: Gly-Gly
  • Compound Class: Bifunctional chimeric peptidomimetic (VTAPP class)
  • Molecular Weight: ~2,600 Da
  • Production: Solid-phase peptide synthesis (SPPS)

Applications

  • In vitro investigation of prohibitin (PHB) and annexin A2 (ANXA2) receptor complex biology in endothelial cell models. Both proteins are expressed in white adipose tissue vasculature and in certain tumor vascular beds, making Adipotide relevant across adipose and oncology research contexts
  • Vascular-targeted apoptosis research. Adipotide’s bifunctional architecture (homing domain + proapoptotic domain) serves as a model system for studying receptor-directed apoptosis induction in specific endothelial cell populations
  • Prohibitin receptor pharmacology. PHB is implicated in breast, prostate, and ovarian cancer vasculature; Adipotide provides a defined molecular tool for probing PHB-mediated signaling and its role in endothelial cell survival
  • White adipose tissue vasculature biology. Studying how endothelial apoptosis affects adipocyte viability, immune resorption mechanisms, and adipose depot remodeling in preclinical models
  • VTAPP platform research. Adipotide represents a well-characterized example of the vascular-targeted proapoptotic peptide design framework; researchers studying chimeric bifunctional peptide architecture use it as a reference compound for this compound class

Storage and Handling

Store as lyophilized powder at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Reconstitute immediately before use in sterile aqueous buffer. Avoid repeated freeze-thaw cycles. As a chimeric peptide with two structurally distinct domains, Adipotide requires careful handling. Verify solubility and aggregation behavior in your target buffer system before preparing working solutions.

Compliance Notice

Adipotide is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms it will use it exclusively for controlled in vitro research following appropriate institutional safety procedures.

Frequently Asked Questions

What is Adipotide?

Adipotide (FTPP) is a synthetic bifunctional peptidomimetic developed from the vascular-targeted proapoptotic peptide (VTAPP) research platform at MD Anderson Cancer Center. It combines a prohibitin/annexin A2-targeting homing sequence (CKGGRAKDC) with a mitochondrial membrane-disrupting proapoptotic domain (KLAKLAK)2. Researchers use it to study receptor-directed endothelial apoptosis in white adipose tissue and tumor vascular models where prohibitin expression is the research target.

How does Adipotide's bifunctional architecture work in research models?

The homing domain (CKGGRAKDC) binds the PHB/ANXA2 receptor complex on target endothelial cells and drives cellular internalization. Once inside the cell, the proapoptotic domain (KLAKLAK)2 engages mitochondrial membranes and initiates the intrinsic apoptosis pathway. The two domains address different biological requirements -- tissue targeting and apoptosis induction -- neither of which functions effectively without the other. Researchers studying this architecture use Adipotide as a model for understanding how bifunctional chimeric peptides achieve tissue-selective cell killing through sequential receptor binding and intracellular effector delivery.

Why is prohibitin relevant beyond adipose tissue research?

Prohibitin (PHB) is expressed on the vascular endothelium of white adipose tissue but has also been identified in the vasculature of certain tumors, including breast, prostate, and ovarian cancers. This shared expression pattern positions Adipotide as a research tool in oncology vascular biology -- the same homing mechanism that targets adipose vasculature may be relevant to tumor vascular research where PHB expression is a variable. Researchers should verify PHB expression in their specific cell model before using Adipotide as a targeting agent.

Related products